Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.
Treatment Considerations in Relapsed Refractory Multiple Myeloma
Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.
Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.
Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.
Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.
Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5